Oppenheimer Initiates Coverage On Monopar Therapeutics with Outperform Rating, Announces Price Target of $77
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Oppenheimer analyst Andreas Argyrides initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Outperform rating and announces Price Target of $77.
Oppenheimer analyst Andreas Argyrides initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Outperform rating and announces Price Target of $77.